365 related articles for article (PubMed ID: 16395746)
1. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
Comby E; Tanaff P; Mariotte D; Costentin-Pignol V; Marcelli C; Ballet JJ
J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
[TBL] [Abstract][Full Text] [Related]
2. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
De Rycke L; Kruithof E; Van Damme N; Hoffman IE; Van den Bossche N; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
[TBL] [Abstract][Full Text] [Related]
3. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
[TBL] [Abstract][Full Text] [Related]
4. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
[TBL] [Abstract][Full Text] [Related]
5. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
[TBL] [Abstract][Full Text] [Related]
6. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
Eriksson C; Engstrand S; Sundqvist KG; Rantapää-Dahlqvist S
Ann Rheum Dis; 2005 Mar; 64(3):403-7. PubMed ID: 15297281
[TBL] [Abstract][Full Text] [Related]
7. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.
Haraoui B; Cameron L; Ouellet M; White B
J Rheumatol; 2006 Jan; 33(1):31-6. PubMed ID: 16395747
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
[TBL] [Abstract][Full Text] [Related]
9. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
Flendrie M; Creemers MC; Welsing PM; van Riel PL
Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
[TBL] [Abstract][Full Text] [Related]
10. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
[TBL] [Abstract][Full Text] [Related]
11. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
Elkayam O; Bashkin A; Mandelboim M; Litinsky I; Comaheshter D; Levartovsky D; Mendelson E; Wigler I; Caspi D; Paran D
Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment.
Paulus HE; Wiesner J; Bulpitt KJ; Patnaik M; Law J; Park GS; Wong WK
J Rheumatol; 2002 Dec; 29(12):2513-20. PubMed ID: 12465144
[TBL] [Abstract][Full Text] [Related]
13. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A
J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
[TBL] [Abstract][Full Text] [Related]
14. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
15. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
Elkayam O; Burke M; Vardinon N; Zakut V; Yitzhak RB; Paran D; Levartovsky D; Litinsky I; Caspi D
Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336
[TBL] [Abstract][Full Text] [Related]
17. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients.
Wolfe F; Michaud K
J Rheumatol; 2004 Nov; 31(11):2115-20. PubMed ID: 15517621
[TBL] [Abstract][Full Text] [Related]
18. Predictors of infusion reactions during infliximab treatment in patients with arthritis.
Kapetanovic MC; Larsson L; Truedsson L; Sturfelt G; Saxne T; Geborek P
Arthritis Res Ther; 2006; 8(4):R131. PubMed ID: 16869978
[TBL] [Abstract][Full Text] [Related]
19. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
20. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients.
Balanescu A; Radu E; Nat R; Regalia T; Bojinca V; Ionescu R; Balanescu S; Savu C; Predeteanu D
Int J Clin Pharmacol Res; 2005; 25(1):9-18. PubMed ID: 15864873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
